Phibro Animal Health Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel Bendheim
- Full Time Employees
- 2,605
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Glenpointe Centre East Teaneck NJ United States of America 07666-6712
- IPO Date
- Apr 11, 2014
- CIK
- 0001069899
- Website
- pahc.com
- Similar Companies
- Business
- Phibro Animal Health Corporation (Nasdaq: PAHC), founded in 1946 and headquartered in Teaneck, New Jersey, develops, manufactures and markets a diversified portfolio of animal health and mineral nutrition products for food-producing animals including poultry, swine, beef cattle, dairy cattle and aquaculture species; its core offerings encompass medicated feed additives, antibacterials, anticoccidials, nutritional specialty products such as OmniGen-AF, vaccines, anthelmintics, mineral nutrition supplements and performance products that enhance feed efficiency, disease prevention and overall livestock health. The company operates through three primary segments--Animal Health, Mineral Nutrition and Performance Products--with the majority of revenue generated from Animal Health, and conducts business across the United States, Latin America, Canada, Europe, the Middle East, Africa and Asia-Pacific via direct sales to integrated producers, feed manufacturers, wholesalers and distributors. In a significant recent development, Phibro completed the acquisition of Zoetis Inc.'s medicated feed additive and water-soluble product portfolio for $350 million in October 2024, integrating over 37 product lines sold in approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and more than 300 employees, which has expanded its offerings across cattle, swine and poultry sectors, boosted net sales by 39% to $378.7 million in fiscal Q4 2025 and driven a 27% full-year sales increase to $1.29 billion. This strategic move complements Phibro's existing capabilities in vaccines and nutritional specialties while diversifying revenue and supporting profitability through enhanced global animal health solutions.
Company News
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Q4 Earnings Call Highlights
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say
Phibro Animal Health (PAHC) Tops Q4 Earnings and Revenue Estimates
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Phibro Animal Health (NASDAQ:PAHC) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Phibro Animal Health Corporation Declares Quarterly Dividend
PAHC vs. SYK: Which Stock Is the Better Value Option?
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
Implied Volatility Surging for Phibro Animal Health Stock Options
Wall Street Analysts Predict a 36.23% Upside in Phibro (PAHC): Here's What You Should Know
PAHC vs. SYK: Which Stock Is the Better Value Option?
What Makes Phibro (PAHC) a New Buy Stock